摘要
目的观察并比较奥沙利铂联合替吉奥或卡培他滨方案在胃癌术后辅助化学治疗中的应用效果。方法将2010年1月至2015年1月收治的老年晚期胃癌初治患者70例,随机分为SOX组(奥沙利铂+替吉奥)和XELOX组(奥沙利铂+卡培他滨),各35例。结果70例患者共治疗327个周期。SOX组治疗167个周期,XELOX组治疗160个周期。SOX组的有效率为62.86%,XELOX组的有效率为51.43%。SOX组的生活质量改善率为85.71%,XELOX组的改善率为65.71%。SOX组较XELOX组不良反应发生率较小。结论 SOX方案比XELOX方案更适合治疗老年晚期胃癌。
Objective To compare the efficacy and adverse reactions of SOX and XELOX chemotherapy used after gastric cancer operation. Methods 70 cases of elderly patients with advanced gastric cancer in the hospital from January 2010 to January 2015 were randomly divided into two groups,35 cases of SOX group,35 cases of XELOX group. Results 70 patients were treated with 327 cycles.SOX group therapy had 167 cycles,XELOX treatment group had 160 cycles. The effectiveness of SOX and XELOX group was 62. 86%,51. 43% respectively. The quality of life improvement rate of SOX and XELOX group was 85. 71%,65. 71% respectively. The incidence of adverse reactions of SOX group was smaller than XELOX group. Conclusion The SOX program is more suitable than XELOX program for the treatment of elderly patients with advanced stomach cancer.
出处
《中国药业》
CAS
2016年第1期103-105,共3页
China Pharmaceuticals
关键词
晚期胃癌
替吉奥
奥沙利铂
卡培他滨
化学治疗
advanced gastric carcinoma
S-1
oxaliplatin
capecitabine
chemotherapy